ArticleThe Kaohsiung journal of medical sciences2026
miR-127-3p Inhibits Cell Stemness and Docetaxel Resistance in Triple-Negative Breast Cancer by Targeting KIF3B.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Kinesins in Cancer Drug Resistance: Mechanisms, Therapeutic Targeting, and Translational Potential.Cancers · 2026Review
- Circulating Extracellular Vesicles Suggest Race-Associated Transcriptomic Differences in Preterm Birth: A Pilot Study.International journal of molecular sciences · 2026Article
- miR-127-3p Inhibits Cell Stemness and Docetaxel Resistance in Triple-Negative Breast Cancer by Targeting KIF3B.The Kaohsiung journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study investigated the mechanism of miR-127-3p in tumor cell stemness and docetaxel (DTX) resistance in triple-negative breast cancer (TNBC). hsa-miR-127-3p and KIF3B levels were predicted using databases and validated in TNBC and paracancerous tissues. KM survival curves were plotted to analyze the effect of miR-127-3p on patient survival. Pearson's analysis was used to determine the correlation between miR-127-3p and KIF3B mRNA in cancer tissues. Drug-resistant TNBC cell lines were established. After transfection, the cell viability, IC50, proliferation, migration, invasion, DTX resistance, apoptosis, and expression of the stemness markers SOX2, OCT4, and Nanog were detected. Databases were used to predict the downstream targets of miR-127-3p. The starBase database and dual-luciferase assay were used to predict and validate the binding relationship of miR-127-3p with KIF3B. Finally, the effect of miR-127-3p on transplanted tumors in TNBC nude mice was verified. miR-127-3p was expressed at low levels in TNBC tissues and was notably associated with shorter survival. Upregulation of miR-127-3p reduced TNBC cell stemness and DTX resistance. miR-127-3p targeted KIF3B. KIF3B overexpression averted the effect of miR-127-3p. miR-127-3p inhibited the growth of transplanted tumors in TNBC nude mice. Overall, miR-127-3p targets KIF3B, thereby reducing TNBC cell stemness and reversing DTX resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.